November 06, 2020
UsAgainstAlzheimer’s Urges FDA to Approve Aducanumab to Give More Time and New Hope to People with Early Stage Alzheimer’s
Washington, D.C. (November 6, 2020) – UsAgainstAlzheimer’s (UsA2) today called for federal regulatory approval of aducanumab, which would be the first disease-slowing Alzheimer’s drug therapy in the U.S., to give
Read more
